Immunotherapy has revolutionized cancer treatment by mobilizing the immune system to attack tumor cells. Major advances, such as immune checkpoint inhibitors (notably against the PD-1 protein), have ...

Endogenous intracellular allosteric modulators of GPCRs remain largely unexplored, with limited binding and phenotype data available. This gap arises from the lack of robust computational methods for ...

where you see this daily pulse of purines being released by Prochlorococcus, this provides a daily inhibition signal that could be causing a pause in SAR11 metabolism, so that the next day when ...

CD38 inhibition is restricted to sUA in purine metabolism, and a structural comparison using methyl analogs of sUA such as caffeine metabolites shows that 1,3-dihydroimidazol-2-one is the main ...

Xanthine oxidase is an essential enzyme within the uric acid metabolic pathway and is required for the breakdown of purine nucleotides ... need for xanthine oxidase inhibition to treat those ...

We believe that XORTX’s expertise in developing XO inhibitors, protected by a ... development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit ...

About Tigulixostat (LC350189, IBI350) Tigulixostat is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.

About Tigulixostat (LC350189, IBI350) Tigulixostat is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase. It ...